Long-term outcomes of direct percutaneous endoscopic jejunostomy: a 10-year cohort

Study aim: To assess the clinical outcomes of patients who received direct percutaneous endoscopic jejunostomy (DPEJ) for enteral feeding.

Materials and methods: This is a 10-year cohort study in a single tertiary center. Main outcome measurements were technical success, and short- and long-term outcomes. DPEJ was attempted in 83 patients (51 men; 55 ± 2 years) for dysphagia (n = 35), gastroparesis with recurrent aspiration (n = 30), and levodopa drug infusion for severe Parkinson's disease (n = 18).

Results: DPEJ was successful in 75 (90%) patients. All technical failures were related to the inability to find adequate trans-illumination, and were not influenced by BMI, age, gender, or indication. Peri-operative (30-day) adverse events occurred in 11 (13%) patients, including wound infection (3), leakage around the stoma (4), minor bleeding requiring no intervention (2), and aspiration (1). There was one case (1.2%) of gastric perforation after PEJ insertion for levodopa drug infusion trial. This 60-year-old woman required an emergency laparotomy with nil complications, and levodopa drug infusion recommenced successfully. One case of intestinal perforation (1.2%) occurred after jejunostomy tube replacement at 6 months of insertion, which was successfully managed with surgery. There were no peri-operative deaths. Adequate delivery of enteral feeding or Duodopa drug was achieved in 66/73 (90%) patients, with evidence of weight gain or improvement in Parkinson's disease. Seven (8%) continued to have clinical regurgitation but not aspiration. After a median follow-up of 84 months, 27 (33%) patients died of their underlying diseases. Seven (8%) had marked improvement in their underlying disease and had PEJ removed after 5 months (range 1–8 months).

Limitations: Single center study.

Conclusions: DPEJ is associated with a high technical success rate (90%), a relatively low rate of peri-operative adverse events (13%) and an improvement in long-term nutritional support in the majority of patients (90%). DPEJ should be the procedure of choice to gain enteral access for feeding or drug delivery prior to considering surgery.

Introduction

Enteral feeding is a critical component of nutritional support in individuals who cannot tolerate adequate oral intake. In patients with a functioning gut, enteral feeding is preferred to parenteral feeding [1–3]. Short-term enteral feeding tubes are placed when such devices are expected to be in situ for less than 30 days duration [4]. For those likely to require long-term feeding (longer than 30 days), multiple options exist including percutaneous endoscopic gastrostomy (PEG), PEG with a jejunal extension tube (PEG), surgical jejunostomy (SJ) or direct percutaneous endoscopic jejunostomy (DPEJ). Enteral nutritional support via PEG is often considered to be the first-line approach as PEG insertion is technically easy and the procedure can be done by most endoscopists. However, gastric feeding via PEG is not suitable for all patients, especially those whose gastric function is impaired (i.e. gastroparesis) or those who are at risk of aspiration pneumonitis [1–3]. In these cases, delivery of nutrients directly to the small intestine is a preferred approach. In addition, DPEJ is able to overcome the frequent tube clogging or obstruction of the thin jejunal extension tube of PEG, providing a more secure and sustained feeding approach. In cases of severe gastroparesis or partial gastric outlet obstruction, the use of DPEJ also allows insertion of a concurrent PEG for venting purposes. First described by Shike et al. in 1987, DPEJ involves the direct insertion of a feeding tube into the proximal small intestine via endoscopic tech-
niques [5]. This modality has gained increasing popularity over the last decade, and provides adequate enteral nutritional support without requiring surgery. Compared to PEGJ, DPEJ has been shown to have lower rates of reintervention (31 % vs. 75 %) [6]. Short-term data have also demonstrated that DPEJ increases body weight and reduces recurrent aspiration pneumonia in patients with a history of aspiration pneumonia [7, 8]. To date, little data currently exist with regard to the long-term clinical outcomes with DPEJ. This study aimed to assess the technical success, complications, and long-term clinical outcomes in patients who received a DPEJ.

Materials and methods

All medical, endoscopic, and surgical records related to all patients who were referred for DPEJ insertion between 2003 and 2013 at the Gastrointestinal Investigation Unit of the Royal Adelaide Hospital, were prospectively collected. Relevant data that were collected included: demographics, body mass index (BMI), comorbidities, indications for DPEJ, procedural success, basic bloods, nutritional status, and progress. The outcomes measured were rates of technical success, short- and long-term complications as well as long-term clinical effects. For each patient, written consent either from the patient or from the legal guardian of the patient was obtained for the procedure. The study was approved by the Human Research Ethics Committee of the Royal Adelaide Hospital. All authors had access to the study data, and reviewed and approved the final manuscript. Exclusion criteria for DPEJ placement included ascites, peritonitis, peritoneal carcinomatosis, coagulation disorders (prothrombin time of less than 50%; thrombocytes less than 50×10^9/L), previous complex upper gastrointestinal surgery, previous placement of an anterior abdominal wall mesh, expected duration of jejunal feeding less than 2 months, and inability to give consent.

Technique

All DPEJs were performed by two experienced interventional endoscopists (MS and NN) using a pediatric colonoscope (Olympus PCF 160AL) and a MIC® Percutaneous Endoscopic Gastrostomy (PEG) kit (20F, Kimberly-Clark, Roswell, GA 30076, USA). All subjects cleansed with local antiseptic and a 22G needle was used to puncture into the lumen of the jejunal loop under direct endoscopic vision (● Fig. 1 b). This was to temporarily fix and secure the relevant jejunal loop to the abdomen wall, allowing time for injection of local anesthesia (lignocaine 2%, 10mL), insertion of a larger bore trocar needle, and a small skin incision (● Fig. 1 c). A plastic loop–wire was then fed through the trocar needle, which was grasped by a snare and pulled out of the mouth by removing the scope (● Fig. 1 d). The PEG tube was attached to the loop-wire, pulled through the mouth into the jejunum and out of the abdominal wall at the DPEJ site (● Fig. 1 e). The inner bumper was retracted against the anterior abdominal wall (● Fig. 1 f) and fixed by a plastic disc (● Fig. 1 g).

Definitions

Technical success was defined as the ability to successfully insert a PEG tube into the proximal jejunum, by the techniques described above, and enable water or enteral feed to be delivered into the small intestine (● Fig. 1 h). Complications were stratified into “major” and “minor”, in which “major” adverse events were defined as those that required surgical interventions or led to death. All other adverse events, such as insertion site infection, leakage, fever, abdominal pain or bleeding, were defined as “mi-
nor”. Peristomal infection was defined as the presence of observed local inflammatory signs such as erythema, induration, and exudate with pain or tenderness.

Data analysis
Most data are expressed as mean ± standard error of mean (SEM). Data that were not normally distributed are expressed as median and range. Comparison of variables was undertaken using Fisher’s exact tests for categorical data, and independent t test or Mann–Whitney test for continuous data sets. Analyses were performed using GraphPad Prism statistical software, version 6 (GraphPad Software Inc., La Jolla, CA, USA). P<0.05 was considered to be statistically significant in all analyses.

Results
Over 10 years, 83 patients (51 men; 55 ± 2 years) underwent DPEJ with the following indications: (i) poor or unsafe oral intake due to dysphagia caused by gastrointestinal malignancy (n = 17), neuromuscular disease (n = 13), previous upper gastrointestinal surgery (n = 5); (ii) aspiration and gastroparesis related to neuromuscular diseases (n = 29) and idiopathic condition (n = 1); and (iii) intrajejunal levodopa infusion for management of severe refractory Parkinson’s disease (n = 18) (Table 1). Twenty-nine (35%) of these patients had been unsuccessfully fed via a PEG with ongoing feed intolerance and respiratory aspiration. Attempts at postpyloric enteral feeding through a PEG-jejunal extension tube in these patients had also failed due to early tube blockage or retroperistomal migration of the intestinal tube into the stomach.

Technical success
Insertion of DPEJ was successful in 75 (90%) patients, and the major reason for technical failure was the inability to identify transabdominal trans-illumination (7/8 failed cases). One unsuccessful attempt was due to altered anatomy with a large hiatus hernia and intrathoracic stomach. Due to the associated multiple comorbidities and high anesthetic risk, only two of eight failed cases were able to undergo surgery for insertion of jejunostomy feeding tube. Overall, there were no significant differences in BMI (21.5 vs. 22.8 kg/m²), age (55.0 vs. 53.8 years), gender (male 61% vs. 50%) or indication of DPEJ between successful and unsuccessful cases.

Short-term outcomes
Peri-operative (30 days) complications occurred in 11 (13%) patients, which included gastric perforation (1), peri-stomal infection (3), leakage around the stoma (4), minor bleeding requiring no intervention (2), and aspiration (1). In all cases, the pain related to the DPEJ insertion settled after 1 week. In the case of gastric perforation, the complication was caused by “piercing the stomach” by the jejunostomy tract, which had been “sandwiched” between the jejunal loop and the abdominal wall. The gastric perforation was closed at laparotomy and the jejunostomy was secured, with levodopa infusion recommencing the next day. There were no no procedural or peri-operative related deaths. Six patients (7%) required DPEJ replacement in less than 6 months due to tube blockage. The mean length of hospital stay for patients who were admitted for the insertion of DPEJ was 4 ± 1 days, whereas it was 72 ± 15 days for those who were already hospitalized for their underlying conditions.

Long-term outcomes
Enteral feeding that matched the patient’s daily requirement was successfully achieved in 95% of patients (n=54/57) with evidence of 7.9 ± 4.2 kg weight gain 3 months after insertion of DPEJ for enteral feeding. Although none of the 30 patients with aspiration due to gastroparesis had further admission due to respiratory aspiration after DPEJ, seven patients continued to report intermittent regurgitation. Intestinal perforation occurred in one patient (1.2%) when the jejunostomy tube was replaced at 6 months post-insertion. This was related to performing push enteroscopy to retrieve the broken bumper, which tore the jejunal loop from the tract. This was successfully managed with surgery. In patients who had DPEJ insertion for levodopa drug infusion (n=18) to treat severe Parkinson’s disease, all apart from two reported a marked improvement in dyskinesia management. One patient failed to respond to levodopa infusion due to severe refractory dyskinesia related to advanced Parkinson’s disease. The other patient suffered from a significant anxiety disorder that resulted in an inability to manage levodopa infusion via the DPEJ, and withdrew from the trial after 1 year of treatment. None of the patients who had the DPEJ insertion for the levodopa infusion had long-term complications. Overall, the mean duration of tube exchange was 8.2 ± 2.1 months; 6 (7%) patients had a tube blockage and required exchange before 6 months. Over the median follow-up period of 84 months, the mean number of exchanges was 3.4 ± 1.8. Seven patients (8%) showed a marked improvement in their underlying diseases, leading to adequate oral intake and removal of DPEJ after a median duration of 5 months (range: 1–8 months). Twenty-seven patients (33%) died from their underlying diseases. Survival was similar between patients who had BMI ≥ 30 kg/m² compared to those with BMI < 30 kg/m² (P=0.78; Fig. 2).

Discussion
This study is one of the largest long-term cohorts to report the outcomes of DPEJ for the delivery of either enteral feeds or medication directly into the proximal intestine for nutritional support or treatment of advanced Parkinson’s disease. The main findings of the study are that insertion of DPEJ is: (i) highly feasi-

Table 1 Summary of demographics and characteristics of the cohort.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>DPEJ cohort (n=83)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years</td>
<td>55 ± 2</td>
</tr>
<tr>
<td>Gender (male/female)</td>
<td>51:32</td>
</tr>
<tr>
<td>Indications for DPEJ</td>
<td></td>
</tr>
<tr>
<td>Dysphagia related to gastrointestinal malignancy</td>
<td>17</td>
</tr>
<tr>
<td>Dysphagia related to neuromuscular disease</td>
<td>13</td>
</tr>
<tr>
<td>Dysphagia from previous upper gastrointestinal surgery (e.g. fundoplication)</td>
<td>5</td>
</tr>
<tr>
<td>Refractory gastroparesis + aspiration</td>
<td>30</td>
</tr>
<tr>
<td>Intrajejunal levodopa infusion for refractory Parkinson’s disease</td>
<td>18</td>
</tr>
<tr>
<td>Previous unsuccessful PEG feeding</td>
<td>29 (35%)</td>
</tr>
<tr>
<td>Mean body mass index (BMI), kg/m²</td>
<td>23.8 ± 0.5</td>
</tr>
<tr>
<td>Mean serum albumin at DPEJ insertion, g/L</td>
<td>29 ± 1.0</td>
</tr>
</tbody>
</table>

BMI, body mass index; DPEJ, direct percutaneous endoscopic jejunostomy; PEG, percutaneous endoscopic gastrostomy.
Compared to previous reports [9–13], which had technical success ranging from 68% to 95%, our study achieved a relatively high technical success with DPEJ insertion (90%). In contrast to the study by Maple et al. in 2005 [11], which found a lower success rate. In fact, successful DPEJ insertion was achieved in all patients with BMI > 30 kg/m² in our study. Instead, the ability to elicit good light trans-illumination and immediate finger-kinesia, respectively; there were no other long-term complications.

Insertion of the DPEJ, however, overcomes these issues and as demonstrated in our study, the long-term success of levodopa infusion was 89% with fewer needs to change the DPEJ (every 6 – 12 months). Two patients required removal due to anxiety and dyskinesia. Direct delivery of a drug, such as levodopa, at a constant rate can avoid such problems, resulting in better control of movement disorders. The therapeutic benefit of this concept has been demonstrated by delivering levodopa through the jejunal extension tube via a PEG (i.e. PEGJ). Unfortunately, the jejunal extension tube is small, easily blocked and requires frequent replacement (ranging from every 1 to 3 months). Insertion of the DPEJ, however, overcomes these issues and as demonstrated in our study, the long-term success of levodopa infusion was 89% with fewer needs to change the DPEJ (every 6 – 12 months). Two patients required removal due to anxiety and dyskinesia, respectively; there were no other long-term complications recorded.

Finally, our study also shed light on the natural history of these patients, in which over one-third died from their underlying diseases or due to extreme technical difficulty (as documented in our exclusion criteria), making our cohort not truly ”unselected”, which may explain the lower complication rate. Most importantly, we have demonstrated that DPEJ leads to a positive long-term outcome, with 95% achieving adequate enteral feeding as evidenced by weight gain (mean of 7.9 ± 2.4 kg) and increase in albumin and hemoglobin. For patients who had aspiration due to gastroparesis, none had further hospital admissions due to respiratory aspiration after DPEJ, though 23% of patients continued to report some ongoing regurgitation. In 8% of patients, there was a marked improvement in the underlying disease after nutritional support, leading to resumption of oral intake and removal of DPEJ. Together, these findings indicate that DPEJ in these difficult patients can not only improve their nutritional support but also reduce the number of hospitalizations due to aspiration pneumonia.

Our study is also the first to report the application of DPEJ as a method of direct drug delivery to improve the management of patients with Parkinson’s disease. It is well known that gastric emptying is impaired and erratic in advanced Parkinson’s disease, leading to an unpredictable rate of drug absorption and poorly controlled dyskinesia. Direct delivery of a drug, such as levodopa, at a constant rate can avoid such problems, resulting in better control of movement disorders. The therapeutic benefit of this concept has been demonstrated by delivering levodopa through the jejunal extension tube via a PEG (i.e. PEGJ). Unfortunately, the jejunal extension tube is small, easily blocked and requires frequent replacement (ranging from every 1 to 3 months). Insertion of the DPEJ, however, overcomes these issues and as demonstrated in our study, the long-term success of levodopa infusion was 89% with fewer needs to change the DPEJ (every 6 – 12 months). Two patients required removal due to anxiety and dyskinesia, respectively; there were no other long-term complications recorded.

Finally, our study also shed light on the natural history of these patients, in which over one-third died from their underlying diseases after a median 84 months follow-up. No death in our cohort was related to the technical complications of DPEJ. Although previous studies have shown a much higher 30-day mortality rate, ranging from 17% to 35%, our cohort consisted of more patients who had advanced malignancy cases as well as other debilitating comorbidities. We had no 30-day mortality, which is most likely...
related to better patient selection as we do not believe that such unwell patients should be subjected to an invasive procedure for little, if any, clinical benefit. The benefit of DPEJ would be best observed in patients with chronic neurological disorders, whose survival is more likely to be years rather than weeks [93, 14, 15]. There were, however, some limitations specific to this study including its single-center nature as well as the use of only a single cohort with no comparison arms. There was also a selection bias towards good procedural candidates, which may be reflective of and applicable to current clinical practice.

In conclusion, DPEJ should be the procedure of choice to gain enteral access for feeding aimed at artificial nutritional support or drug delivery before considering surgery or PEG-jejunal extension due to its high technical success rate (90%), low incidence of complications (13%) with the majority being minor complications managed conservatively, low re-intervention rate, and its positive impact on long-term outcomes.

**Competing interests:** None

**References**